Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

Table 3 Changes in TSQM, 6MWD, medication administration time, and adverse events associated with transitioning from inhaled iloprost to inhaled treprostinil

	Baseline	Week 12	Absolute change	Standard effect size	p
TSQM, mean ± SD
Effectiveness	62 ± 10	82 ± 16	+20 ± 21	2.0	<0.0001
Side effects	85 ± 21	85 ± 18	0 ± 22	0	0.97
Convenience	44 ± 24	83 ± 17	+39 ± 26	1.6	<0.0001
Global satisfaction	61 ± 23	82 ± 18	+20 ± 24	0.9	<0.0001
6-minute walk distance, mean ± SD, m	395 ± 79	414 ± 84	+16 ± 35	0.2	0.0005
Medication administration time, mean ± SD, min./day
Gather supplies	21 ± 24	12 ± 11	−9 ± 26	0.4	0.01
Prepare system	11 ± 8	9 ± 9	−2 ± 12	0.3	0.16
Inhalation	66 ± 35	13 ± 7	−53 ± 37	1.5	<0.0001
Clean	21 ± 47	5 ± 4	−16 ± 46	0.3	0.01
Total time	119 ± 78	39 ± 25	−80 ± 81	1.0	<0.0001
Adverse events, median (IQR)
Severity-weighted adverse event score	-	4.4 ± 2.8	-	-	-

ISSN: 1477-7525